ANTIHYPERTENSIVE TREATMENT WITH COMBINED DRUG OF LOSARTAN AND HYDROCHLOROTHIAZIDE
Aim: to evaluate efficiency and safety of the combined antihypertensive drug Lozap Plus (50 mg losartan, 12,5 mg hydrochlorothiazide) in patients with arterial hypertension (AH) of I-III grade with high and very high cardiovascular risk. Material and methods: 30 patients with AH of I-III grade (13...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2016-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/999 |
| _version_ | 1797232317509402624 |
|---|---|
| author | R. M. Linchak K. M. Shumilova A. D. Martinyuk T. A. Gusaim E. V. Semyonova L. G. Zhirova S. A. Boitsov |
| author_facet | R. M. Linchak K. M. Shumilova A. D. Martinyuk T. A. Gusaim E. V. Semyonova L. G. Zhirova S. A. Boitsov |
| author_sort | R. M. Linchak |
| collection | DOAJ |
| description | Aim: to evaluate efficiency and safety of the combined antihypertensive drug Lozap Plus (50 mg losartan, 12,5 mg hydrochlorothiazide) in patients with arterial hypertension (AH) of I-III grade with high and very high cardiovascular risk. Material and methods: 30 patients with AH of I-III grade (13 men and 17 women aged 51.9±1.9) were observed. Patients received Lozan Plus (Zentiva, Czech Republic) 1 time in the morning during 12 weeks. Ambulatory blood pressure monitoring (ABPM), echocardiography, biochemical blood analysis were carried out, microalbuminuria (MA) was determined, quality of life was assessed. Results: After 2 weeks of therapy decrease in office systolic blood pressure (BP) was observed, and after 4 weeks - in diastolic BP. After 12 weeks of treatment decrease in BP became more significant. Target systolic and diastolic BP was reached in 83.3% and 90% of patients respectively. Decrease in systolic BP was observed in 24 hrs. (from 141.9±1.9 to 128.6±0.8 mmHg, p<0.001), in daytime (from 146.8±2.6 to 135.8±1.0 mmHg, p<0.01) and in nighttime (from 131.5±1.9 to 118.8±1.9 mmHg, p<0.001). Diastolic BP also decreased: in 24 hrs. (from 91.7±1.8 to 78.7±1.6 mmHg, p<0.05), in daytime (from 94.3±1.3 to 85.0±1.2 mmHg, p<0.05) and in nighttime (from 83.5±2.0 to 71.2±1.7 mmHg, p<0.01). Daily variability of BP, time index of BP and morning BP rise (from 37.6±2.0 to 23.9±1.9 mmHg, p<0.001) reduced. Normalization of daily profile of BP was observed in the majority of patients after 12 weeks of Lozap Plus therapy. Treatment resulted in reduction of number of patients with myocardial hypertrophy (from 50% to 30%, p<0.01), and of patients with diastolic dysfunction of left ventricle (from 43.3% to 30%, p<0.05). Therapy with Lozap Plus during 12 weeks was followed by decrease in MA from 56.7±1.1 mg/l to 9.0±0.5 mg/l. Lozap Plus demonstrated metabolic safety by assessing carbohydrate, lipid, nitric and electrolyte blood parameters. Increase in quality of life was observed by week 12 of treatment. Conclusion: Lozap Plus is efficient antihypertensive drug providing cardio- and nephroprotection, which doesn’t cause metabolic disturbances and improves quality of life of hypertensive patients. |
| first_indexed | 2024-03-08T14:03:23Z |
| format | Article |
| id | doaj.art-b78ed7f1e3bc41fdb579f7982d127431 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-04-24T15:58:21Z |
| publishDate | 2016-01-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-b78ed7f1e3bc41fdb579f7982d1274312024-04-01T07:43:31ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-01-0121182410.20996/1819-6446-2006-2-1-18-24998ANTIHYPERTENSIVE TREATMENT WITH COMBINED DRUG OF LOSARTAN AND HYDROCHLOROTHIAZIDER. M. Linchak0K. M. Shumilova1A. D. Martinyuk2T. A. Gusaim3E. V. Semyonova4L. G. Zhirova5S. A. Boitsov6National Pirogov medico-surgical centre of RoszdravNational Pirogov medico-surgical centre of RoszdravNational Pirogov medico-surgical centre of RoszdravNational Pirogov medico-surgical centre of RoszdravNational Pirogov medico-surgical centre of RoszdravNational Pirogov medico-surgical centre of RoszdravNational Pirogov medico-surgical centre of RoszdravAim: to evaluate efficiency and safety of the combined antihypertensive drug Lozap Plus (50 mg losartan, 12,5 mg hydrochlorothiazide) in patients with arterial hypertension (AH) of I-III grade with high and very high cardiovascular risk. Material and methods: 30 patients with AH of I-III grade (13 men and 17 women aged 51.9±1.9) were observed. Patients received Lozan Plus (Zentiva, Czech Republic) 1 time in the morning during 12 weeks. Ambulatory blood pressure monitoring (ABPM), echocardiography, biochemical blood analysis were carried out, microalbuminuria (MA) was determined, quality of life was assessed. Results: After 2 weeks of therapy decrease in office systolic blood pressure (BP) was observed, and after 4 weeks - in diastolic BP. After 12 weeks of treatment decrease in BP became more significant. Target systolic and diastolic BP was reached in 83.3% and 90% of patients respectively. Decrease in systolic BP was observed in 24 hrs. (from 141.9±1.9 to 128.6±0.8 mmHg, p<0.001), in daytime (from 146.8±2.6 to 135.8±1.0 mmHg, p<0.01) and in nighttime (from 131.5±1.9 to 118.8±1.9 mmHg, p<0.001). Diastolic BP also decreased: in 24 hrs. (from 91.7±1.8 to 78.7±1.6 mmHg, p<0.05), in daytime (from 94.3±1.3 to 85.0±1.2 mmHg, p<0.05) and in nighttime (from 83.5±2.0 to 71.2±1.7 mmHg, p<0.01). Daily variability of BP, time index of BP and morning BP rise (from 37.6±2.0 to 23.9±1.9 mmHg, p<0.001) reduced. Normalization of daily profile of BP was observed in the majority of patients after 12 weeks of Lozap Plus therapy. Treatment resulted in reduction of number of patients with myocardial hypertrophy (from 50% to 30%, p<0.01), and of patients with diastolic dysfunction of left ventricle (from 43.3% to 30%, p<0.05). Therapy with Lozap Plus during 12 weeks was followed by decrease in MA from 56.7±1.1 mg/l to 9.0±0.5 mg/l. Lozap Plus demonstrated metabolic safety by assessing carbohydrate, lipid, nitric and electrolyte blood parameters. Increase in quality of life was observed by week 12 of treatment. Conclusion: Lozap Plus is efficient antihypertensive drug providing cardio- and nephroprotection, which doesn’t cause metabolic disturbances and improves quality of life of hypertensive patients.https://www.rpcardio.online/jour/article/view/999losartanhydrochlorothiazidearterial hypertensionmyocardial hypertrophymicroalbuminuriaquality of life |
| spellingShingle | R. M. Linchak K. M. Shumilova A. D. Martinyuk T. A. Gusaim E. V. Semyonova L. G. Zhirova S. A. Boitsov ANTIHYPERTENSIVE TREATMENT WITH COMBINED DRUG OF LOSARTAN AND HYDROCHLOROTHIAZIDE Рациональная фармакотерапия в кардиологии losartan hydrochlorothiazide arterial hypertension myocardial hypertrophy microalbuminuria quality of life |
| title | ANTIHYPERTENSIVE TREATMENT WITH COMBINED DRUG OF LOSARTAN AND HYDROCHLOROTHIAZIDE |
| title_full | ANTIHYPERTENSIVE TREATMENT WITH COMBINED DRUG OF LOSARTAN AND HYDROCHLOROTHIAZIDE |
| title_fullStr | ANTIHYPERTENSIVE TREATMENT WITH COMBINED DRUG OF LOSARTAN AND HYDROCHLOROTHIAZIDE |
| title_full_unstemmed | ANTIHYPERTENSIVE TREATMENT WITH COMBINED DRUG OF LOSARTAN AND HYDROCHLOROTHIAZIDE |
| title_short | ANTIHYPERTENSIVE TREATMENT WITH COMBINED DRUG OF LOSARTAN AND HYDROCHLOROTHIAZIDE |
| title_sort | antihypertensive treatment with combined drug of losartan and hydrochlorothiazide |
| topic | losartan hydrochlorothiazide arterial hypertension myocardial hypertrophy microalbuminuria quality of life |
| url | https://www.rpcardio.online/jour/article/view/999 |
| work_keys_str_mv | AT rmlinchak antihypertensivetreatmentwithcombineddrugoflosartanandhydrochlorothiazide AT kmshumilova antihypertensivetreatmentwithcombineddrugoflosartanandhydrochlorothiazide AT admartinyuk antihypertensivetreatmentwithcombineddrugoflosartanandhydrochlorothiazide AT tagusaim antihypertensivetreatmentwithcombineddrugoflosartanandhydrochlorothiazide AT evsemyonova antihypertensivetreatmentwithcombineddrugoflosartanandhydrochlorothiazide AT lgzhirova antihypertensivetreatmentwithcombineddrugoflosartanandhydrochlorothiazide AT saboitsov antihypertensivetreatmentwithcombineddrugoflosartanandhydrochlorothiazide |